FAQs

Documentation (New 2-26-19)

EFIC

Equipment/Trial Materials (New 2-26-19)

ICP Placement Procedure and Pbt02 Probes (New 2-26-19)

Investigator Meetings

IRB (Updated 2-27-19)

Protocol/Protocol Adherence (New 2-26-19)

SIREN CCC and Site Contacts

Sites

Subject Reimbursement/Finances (New 2-26-19)

Training

Treatment Tiers (Updated 2-28-19)

WebDCU

Other (New 2-26-19)

 


Documentation

Q: How do we record 2 abnormalities that occur within one hour?

A: If an abnormal ICP or PbtO2 is corrected and then becomes abnormal again within one hour, treat as one episode. May select treatments from Tier 1, 2, 3.

Example: ICP was reduced after initiating treatment from Tier 1 in 10min, but back up within the hour. These two Scenarios (2 abnormalities) occurred within one hour and should be considered one Scenario.

top

 

ICP Placement Procedure and Pbt02 Probes

Q: Will this be an inpatient or outpatient procedure?

A: This is an inpatient treatment protocol with all procedures being done in the hospital setting.

 

Q: How long will the ICP placement procedure and PbtO2 probes take? Where will this procedure be performed?

A: The procedure takes approximately 20-30 minutes. This procedure is performed most commonly in the intensive care unit. In some occasions it is performed in the operating room if the patient requires a surgical procedure. In rare cases, in some institutions, the probes are placed in the emergency department.

 

Q: Will there be anesthesia required for placement of intracranial monitors?

A: Yes. In the intensive care unit or emergency department, the probes are placed under local anesthesia with moderate or unconscious sedation protocols. If the probes are being placed in the operating room, there is no need for additional sedation or anesthesia as they are typically being placed under for other surgical procedures that are determined to be necessary by the treating neurosurgeon.

top

 

Protocol/Protocol Adherence

Q: Is it required that the treatment team always adhere to the protocol?

A: Yes, adherence to the protocol is required. There is substantial room within each Scenario and within each Tier for neurointensivists at each site to choose the particular intervention to implement, which should be informed by the detailed knowledge of the pathophysiology active in a particular patient at a particular time. The treatment team may choose not to do interventions responding to an abnormal PbtO2 or ICP for medical/safety reasons. However, for Tiers 1 and 2, the available treatment options are broad enough that it would be highly unusual that all of the treatment options would be contraindicated in a given patient. Tier 3 treatments are optional in all cases and are included in the CRFs so we can record therapies that could be instituted. If site investigators chose not to implement any Tier 1 or Tier 2 therapies, the rationale for that decision needs to be clearly documented in the medical chart and recorded by the research team to avoid protocol violations.

top

 

SIREN CCC and Site Contacts

Q: Who are the personnel at the SIREN CCC and who should we communicate with for various trial related questions?

A: The easiest way to reach out to the SIREN CCC is to use the BOOST-contact@umich.edu.  This will ensure that your message gets to the appropriate team member who can provide a prompt response.
 

Q: How can we confirm prospective trial sites, affiliated SIREN Hubs and critical study team member contact information with the SIREN CCC?

A: This is a great question, as we want to be sure that we have the contact information to reach all critical study team members at all prospective BOOST 3 sites.  If there have been any changes to your site's Hub affiliation, BOOST 3 PI, or BOOST 3 Primary Study Coordinator since you completed the intiial survey, please let us know.   We are happy to work with you to confirm this information.

top

 

Treatment Tiers

Q: What if a treatment that is listed in the Tiers is already being done prior to a new episode?

A: Only treatments initiated AFTER an episode has begun in response to that episode should be entered on the case report form (CRF). The CRF will document the time of the new episode, and any new treatment initiated. If the treatment was already being actively used before the episode started, it should NOT be entered on the CRF as a new treatment. Treatments already being actively used when an episode occurs should be noted, but NOT listed as a new treatment initiated in response to the abnormality for this new episode. Select another treatment from Tier 1 to address the new episode or select from Tier 2 if Tier 1 treatments are already actively being used and the treatment team chooses not to do another treatment from Tier 1. Note this information and rationale.

Examples:

  • If the head of bed is already elevated when the ICP increases to begin a new episode, the raising head of bed is not a new treatment unless the head of the bed is raised further.
  • If any intervention is given for an episode of elevated ICP and the ICP responded, then that episode has resolved in response to the treatment(s) given. This is documented in the CRF. If a few hours later, there is another episode of elevated ICP, the team can choose to give any tier 1 treatment again, including the agent given for the earlier episode, if it is felt to be clinically indicated. This is a considered a new intervention for a new event.

top

 

BOOST-3 Sites

Q: How will sites be rolling out and how many sites will participate in the study?

A: While taking all sites into consideration, we will be prioritizing sites based on experience with placement and management of PbtO2 monitors.  We will be contacting the highest priority sites no later than September 10. BOOST will only include sites that use PbtO2 monitors. For sites who do not currently have or use PbtO2 monitors but intend to, you will need to demonstrate experience in using brain tissue  oxygen monitors for patient care in TBI patients. Our expectation is that sites should have successfully placed and used PbtO2 monitors at least 3 times in the past 6 months to be considered as a BOOST site. After your site has placed at least 3 PbtO2 monitors, the site PI should contact Dr. Shutter (shutterla@upmc.edu) to confirm this information.  We encourage all sites to begin preparations now, and will move forward with sites as they complete this process and are ready to get started.  We budgeted for 45 actively enrolling sites in BOOST3.

top

 

IRB

Q:  Does my site have to use the Central/Single IRB?   

A: Yes. BOOST-3 is an NIH-funded study awarded after Jan. 25, 2018. The NIH requires mandatory use of a single IRB for all SIREN trials (NIH Policy).  

 

Q:  What is the Central IRB #?   

A: Pro00030585

 

Q:  What will be involved in the process of ceding to the central IRB (Advarra)?   

A: Consistent with NIH guidelines, BOOST 3 will be using a central IRB.  The answer to this question and others about cIRB can be found on the following SIREN page: Resources and Steps for Relying on the SIREN ER-CIRB

 

Q: My site IRB uses Smart IRB for reliance agreements.  How does that work?

A: Please contact your IRB for assistance with this.  You can also reference instructions from Advarra: Using Smart IRB

top

 

EFIC

Q: What is expected of each site for the EFIC process for this trial?

A: Sites with experience conducting EFIC activities can expect to propose community consultation and public disclosure (CC/PD) activities similar to the efforts undertaken in previous trials.  However, the cIRB may yet request the overall trial EFIC plan to have some additional or different requirements. An EFIC plan for sites to use to build out your local CC/PD plan will be made available as soon as it has been cIRB approved.  Centrally, the CCC will create CC/PD related resources and templates for local use, e.g, videos, brochures, ads, flyers, slide sets, self-administered survey instruments, etc. CC and PD results and event data will be collected centrally in WebDCU™ for generating reports for the cIRB.  There will be startup funds allocated to perform the required EFIC activities. If you have additional questions please contact Deneil Harney dkolk@umich.edu 734-232-2132

top

 

WebDCU™

Q: How will BOOST 3 data be managed?

A: The BOOST 3 database is currently being built in the WebDCU™ clinical trial management system.   WebDCU is housed at the Data Coordination Center (DCC) at the Medical University of South Carolina (MUSC).  All trial data will be maintained in this secured system, including CRFs, regulatory requirements, and EFIC CC and PD activities.  The central IRB application process will also take place in this system. Training and instructional materials will be provided to facilitate use of each component of the database.

top

 

Training

Q: How will local site training take place?

A: Sites will be responsible for training their local study teams and clinical staff initially and throughout the course of the trial.  The SIREN CCC will provide training materials, available online for easy access (protocol training, in-service slides, etc.), as well as study materials to be distributed locally (e.g. pocket cards, trial posters, etc.).  As sites develop their own materials, we encourage sharing across the network and can post these materials in the BOOST 3 Toolbox.

top

 

Equipment/Trial Materials

Q: What trial equipment will be provided to sites?

A: The SIREN CCC will be lending Moberg CNS monitors (CNS-310) to all enrolling sites.  So long as sites continue to enroll, the devices will remain on site. Should sites discontinue enrollment, the devices will be returned to the SIREN CCC.  Pbt02 monitors will NOT be provided by the SIREN CCC. For enrolling sites, startup payments will include some funds to partially offset the cost of site’s PbtO2 ownership, and may be applied to equipment necessary to connect the PbtO2 device (Integra Licox or Raumedic Neurovent) to the Moberg monitor.  The cost of probes is built into per subject payments.

 

Q: What do you do if it appears that the PbtO2 monitor is not functioning properly?

A: If there is evidence that a probe is not working and a first and second FiO2 challenge has failed, follow the next steps as outlined in the MOP (CT and replacement in the unblinded group) and in the blinded group just check it every day with one FiO2 challenge.

If after replacement of the probe, the new probe still fails the FiO2 challenge, the team may then choose to ignore the PbtO2 numbers. The protocol does not require replacing the probe a second time.

If FiO2 challenges in subsequent days show that the probe starts working (i.e., the FiO2 challenge is successful), interventions for low PbtO2 can be re-started. In all cases, the primary analysis will be performed using intention to treat principles.

top

 


Subject Reimbursement/Finances

Q: What is the per subject reimbursement?

A: The per subject reimbursement has not yet been finalized.  However, it is expected to be approximately $12,500, which is inclusive of indirects.  Per subject reimbursement will be milestone driven.

 

Q: Are we billing insurance for the procedure?

A: Yes.  Placement of probes are considered routine care of TBI patients at all study sites.

 

Q: Are we billing insurance for the device?

A: The ICP probe is standard of care and the cost of the probe should be billed to the 3rd party payors.  The PbtO2 probe is the target of the study, and the cost of the probe is included in the per-patient capitated cost. There is no charge for the use of the Moberg CNS monitor. 

 

Q: Will the sponsor pay for the device or procedure if insurance denies?

A: No. As placement of the probes is part of routine care, the cost for the procedure to place the probes and the ICP probe itself should be billed to insurance. The cost of the PbtO2 probe is covered by the sponsor. There is no cost associated with the monitoring device. As a reminder: Please discuss your local practices for intracranial monitoring with the treating neurointensivist or neurosurgeon at your site.

top

 

Investigator Meetings

Q: Will there be an initial BOOST 3 Investigator Meeting?

A: Yes.  We anticipate that this will take place in the first quarter of 2019.  Meeting details and location will be distributed as soon as we have further information.

 
 

Other

Q. What is the management strategy for the BOOST-3 trial?

A. BOOST-3 is a trial assessing a management strategy of patient care; it is NOT a study assessing an experimental drug, device or procedure. The procedures being done for this trial, including placement of intracranial monitoring probes, is part of the routine care for patients admitted to the hospital (i.e. inpatients) with severe TBI.

 

Q. Do you have the IDE #?

A. No, there is an IDE waiver from the FDA since PbtO2 devices are FDA-cleared for this indication.

 

Q. Where can I get more information on Integra/Raumedic products or their IFUs?

A. Integra: http://www.integralife.eu/products/neuro/neurocritical-care/pbto2-licox/

    Raumedic: https://www.raumedic.com/us/neuromonitoring/neuro-icu/oxygen-partial-pressure/

top